Mediators of Inflammation

Atherosclerosis in Rheumatoid Arthritis

Publishing date
02 Nov 2012
Submission deadline
15 Jun 2012

1Rheumatology Division, Marqués de Valdecilla University Hospital, IFIMAV, Santander, Spain

2Department of Rheumatology, Institute of Medicine, University of Debrecen Medical and Health Sciences Center, 98 Nagyerdei Street, 4032 Debrecen, Hungary

3Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

4Department of Rheumatology, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, Johannesburg, Johannesburg, South Africa

Atherosclerosis in Rheumatoid Arthritis


Cardiovascular complications constitute the leading cause of death in patients with rheumatoid arthritis. Patients with this complex polygenic inflammatory rheumatic disease have metabolic abnormalities including a dyslipidemic pattern and insulin resistance. Surrogate markers of atherosclerosis have disclosed the presence of subclinical atherosclerosis in these patients. Besides genetic factors, chronic inflammation plays a pivotal role in the development of accelerated atherosclerosis in rheumatoid arthritis. Since the advent of biologic therapies for the management of rheumatoid arthritis, the incidence of cardiovascular complications seems to have decreased in patients with this disease. However, further studies are needed to shed light on the problem of augmented risk of cardiovascular disease in patients with rheumatoid arthritis.

Articles for this special issue on mechanisms associated with atherosclerosis in patients with rheumatoid arthritis are welcome. Potential topics include, but are not limited to:

  • Influence of genetic factors
  • Role of biomarkers of endothelial dysfunction
  • Influence of proinflammatory cytokines
  • The role of CRP as a marker of atherosclerosis
  • The presence of metabolic syndrome and insulin resistance
  • The influence of classic cardiovascular risk factors
  • The role of inflammation in the development of dyslipidemia
  • The implication of surrogate markers of atherosclerosis
  • The influence of biologic therapies, in particular TNF antagonist agents, on the modulation of endothelial dysfunction and cardiovascular risk of patients with rheumatoid arthritis

Before submission authors should carefully read over the journal's Author Guidelines, which are located at Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at according to the following timetable:

Mediators of Inflammation
 Journal metrics
Acceptance rate36%
Submission to final decision53 days
Acceptance to publication29 days
Journal Citation Indicator0.610
Impact Factor4.711

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.